Eli Lilly shares climbed 4% in premarket trading on Monday after the company disclosed full results from two clinical trials of its next-generation obesity therapy, retatrutide. The data were presented at the American Diabetes Association meeting in New Orleans and covered one study in treatment-naive type 2 diabetes patients and another in people with obesity.
Market participants focused particularly on the efficacy of the 4 mg dose, which achieved roughly 19% weight loss - a result described as comparable to the highest dose of the current blockbuster therapy Zepbound. Analysts and investors also noted tolerability findings were largely similar to competitors, with comparable rates of treatment discontinuation and relatively low levels of vomiting reported. The trials did show that adverse effects rose at higher retatrutide doses.
Analysts at Citi highlighted the clinical implications of the 4 mg data, writing that, "The 4mg dose efficacy data for retatrutide are compelling enough that first-line positioning cannot be dismissed," and adding that the drug may serve as "the next step for patients who have exhausted Lilly’s tirzepatide efficacy."
J.P. Morgan analyst Chris Schott echoed the positive read on Lilly’s positioning, saying, "LLY has the pieces in place to further raise the standard of care in the obesity space, and we see the company if anything further extending its leadership position in the $200bn+ incretin/obesity market longer term."
Beyond retatrutide, Lilly released additional data on other obesity-related candidates, including its approved weight-loss pill and an experimental injectable called eloralintide. RBC Capital Markets analyst Trung Huynh commented on the breadth of Lilly’s pipeline, saying the depth of the obesity portfolio "highlighted its leadership growing rather than a narrowing gap with competitors."
On a year-to-date basis, Lilly shares have risen 5.2% following a significant rally in 2025. By contrast, Novo Nordisk, identified as Lilly’s closest rival in the obesity space, has experienced an approximate 15% decline so far this year.
Market context - The data release and analyst reaction underline how efficacy at lower doses and acceptable tolerability can influence competitive positioning in the obesity therapy market. Investors appear to be prioritizing regimens that balance substantial weight loss with manageable side-effect profiles.